Cornerstone Investment Partners and at least three billionaire-backed family offices initiated or expanded positions in Taiwan Semiconductor Manufacturing during Q4 2024, deploying an estimated $847 million across new and expanded stakes. The timing aligns with the second delay of TSM's Arizona fab, now scheduled for volume production in late 2026, and Intel's admission that its 18A node remains commercially unproven.

The buying follows a pattern established in late 2023 when allocators treated US onshoring rhetoric as noise and Taiwan's fabrication lead as structural fact. TSM now commands 54 percent of the global foundry market by revenue, with its 3nm process already shipping in volume while US-based competitors remain stuck at 5nm or coarser geometries. The company reported $20.1 billion in Q4 revenue, up 38.8 percent year-over-year, driven by AI accelerator demand from Nvidia, AMD, and unnamed hyperscale clients. Gross margin held at 57.8 percent despite Arizona construction costs eating $2.3 billion in non-recurring expenses.

The allocator thesis rests on three facts: TSM's Arizona operation will produce chips at 40 percent higher cost than Taiwan fabs due to labor and equipment installation premiums; the CHIPS Act disbursed only $6.1 billion of its $39 billion allocation through December 2024, with most recipients missing buildout milestones; and no Western fab has demonstrated the ability to match TSM's 3nm yield rates, which the company reports at above 80 percent for high-performance compute dies. Apple's A17 Pro and M3 chips, Nvidia's H100 successor, and AMD's MI300 variants all depend on Taiwanese fabs with no credible alternative before 2027.

The intelligence-desk interpretation: billionaire allocators are treating US chip policy as a subsidy for domestic employment, not a viable path to supply-chain independence. TSM's Arizona facility will serve as a political hedge and a high-cost backup for defense contractors, but volume economics remain in Hsinchu. Family offices that added exposure in Q4 are positioning for AI infrastructure buildout through 2026, betting that hyperscalers will pay TSM's prices rather than wait for Intel's 18A or Samsung's unproven 2nm node.

The risk calculus shifted in November when TSM management confirmed it would allocate only 12 percent of 2025 capex to US operations, down from the 18 percent originally signaled. The company is instead expanding Fab 21 in Taiwan and accelerating 2nm pilot production, scheduled for risk production in Q2 2025. CoWoS-S advanced packaging capacity, the bottleneck for AI accelerators, remains entirely Taiwan-based with no US equivalent before 2027.

Operators and allocators should watch for three follow-on events: Intel's 18A customer announcements in March, which will reveal whether Amazon or Microsoft commit to non-TSM silicon; TSM's April earnings call, where management will clarify Arizona fab volume ramp timelines and subsidy disbursement; and Nvidia's GB200 NVL72 rack shipment data in May, which will confirm whether CoWoS packaging constraints persist. The Japan Fab 2 groundbreaking in Kumamoto, scheduled for February, offers a window into TSM's non-US capacity expansion strategy.

TSM closed at $187.34 on Friday, up 88.7 percent from its October 2023 low. The allocator money entered between $165 and $178, suggesting conviction that the stock's 32x forward earnings multiple is justified by monopoly position rather than growth narrative. If Intel's 18A fails to attract hyperscale clients by midyear, TSM's pricing power expands further.